Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q1 2024 Results Conference Call May 9, 2024 4:30 PM ET

Company Participants

Sara Pellegrino - Senior Vice President, Investor Relations & Corporate Communications
Dr. Fred Vogt - Interim President & Chief Executive Officer
Jim Ziegler - Executive Vice President, Commercial
Dr. Igor Bilinsky - Chief Operating Officer
Jean-Marc Bellemin - Chief Financial Officer
Dr. Friedrich Finckenstein - Chief Medical Officer
Dr. Brian Gastman - Executive Vice President, Medical Affairs
Dr. Raj Puri - Executive Vice President, Regulatory Strategy & Translational Medicine

Conference Call Participants

Michael Yee - Jefferies
Andrea Tan - Goldman Sachs
Peter Lawson - Barclays
Tyler Van Buren - TD Cowen
Yanan Zhu - Wells Fargo Securities
Colleen Kusy - Baird
Asthika Goonewardene - Truist
Joe Catanzaro - Piper Sandler
Reni Benjamin - JMP Securities
Ben Burnett - Stifel

Operator

Welcome to the Iovance Biotherapeutics Conference Call to discuss the First Quarter 2024 Results and recent Corporate Updates. My name is Livia, and I'll be your operator for today's call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session. Please note that this conference is being recorded.

I will now hand the conference call over to Sara Pellegrino, Senior Vice President, Investor Relations and Corporate Communications at Iovance. Sarah, you may begin.

Sara Pellegrino

Thank you, operator. Good afternoon and thank you for joining this conference call and webcast to discuss our first quarter 2024 results and recent corporate update.

Dr. Fred Vogt, our Interim President and Chief Executive Officer will provide an introduction and summarize key updates on our U.S. Commercial launch of Amtagvi and our pipeline program.

Jim Ziegler, EVP Commercial, will highlight our initial insights for the U.S. commercial launch of Amtagvi, in advanced melanoma. Dr. Igor Bilinsky, COO, will highlight commercial manufacturing and capacity expansion plans. Jean-Marc Bellemin, CFO will review our financial results.

And Dr. Friedrich Finckenstein, Chief Medical Officer, will review key pipeline update including upcoming clinical data presentations at ASCO and new next generation approaches. Dr. Brian Gastman, Executive Vice President, Medical Affairs; and Dr. Raj Puri, Executive Vice President, Regulatory Strategy are also on the call and available for the Q&A session.

Earlier this afternoon, we issued a press release that can be found on our corporate website at iovance.com.

Before we start, I would like to remind everyone that statements made during this conference call will include forward-looking statements regarding Iovance's goals, business focus, business plans and transactions, revenue, commercial activities, clinical trials and results, regulatory approvals and interactions, plans and strategies, research and preclinical activities, potential future applications of our technologies, manufacturing capabilities, regulatory feedback and guidance, payer interactions, licenses and collaboration, cash position and expense guidance, and future updates.